Skip to main content

Table 2 Summary of ongoing clinical trials using new generation of CAR T cells in solid tumors

From: Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment

Intervention Phase Treated cancers Primary outcome measures Clinical Trials Identifier Status
CTLA-4/PD-1 antibody expressing mesothelin-CAR T cells I/II Advanced solid tumor Number of adverse events NCT03182803 Recruiting
PD-1 antibody expressing mesothelin-specific CAR T cells I/II Advanced solid tumor Safety profile of treatments NCT03030001 Recruiting
CTLA-4/PD-1 antibody expressing MUC-1 CAR T cells I/II Advanced solid tumor Safety and toxicity profile of treatments NCT03179007 Recruiting